{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:07:56Z","timestamp":1789650476411,"version":"4.0.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The presence of a disease continuum in inflammatory arthritis (IA) is a recognised concept, with distinct stages from at-risk stage (presence of anti citrullinated-peptide autoantibody) to diagnosis of rheumatoid arthritis (RA), including therapy-induced remission. Despite T-cell dysregulation being a key feature of RA, there are few reports of T-cell phenotyping along the IA-continuum. We investigated the disturbances of na\u00efve, regulatory and inflammation related cell (IRC) CD4+ T-cell subsets in 705 individuals across the IA-continuum, developing a simple risk-score (summing presence\/absence of a risk-associated with a subset) to predict progression from one stage to the next. In 158 at-risk individuals, the 3 subsets had individual association with progression to IA and the risk-score was highly predictive (p\u2009&lt;\u20090.0001). In evolving IA patients, 219\/294 developed RA; the risk-score included na\u00efve and\/or Treg and predicted progression (p\u2009&lt;\u20090.0001). In 120 untreated RA patients, the risk-score for predicting treatment-induced remission using na\u00efve T-cells had an odds ratio of 15.4 (p\u2009&lt;\u20090.0001). In RA patients in treatment-induced remission, a score using na\u00efve T-cells predicted disease flare (p\u2009&lt;\u20090.0001). Evaluating the risk of progression using na\u00efve CD4+ T-cells was predictive of progression along the whole IA-continuum. This should allow identification of individuals at high-risk of progression, permitting targeted therapy for improved outcomes.<\/jats:p>","DOI":"10.1038\/s41598-020-60314-w","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T11:02:41Z","timestamp":1582887761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum:\u00a0implications for management"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3969-7701","authenticated-orcid":false,"given":"Frederique","family":"Ponchel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3321-9087","authenticated-orcid":false,"given":"Agata N.","family":"Burska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya H.","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-5665","authenticated-orcid":false,"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8482","authenticated-orcid":false,"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"60314_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/ard.2010.143396","volume":"70","author":"J Lindhardsen","year":"2011","unstructured":"Lindhardsen, J. et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Annals of the rheumatic diseases 70, 929\u2013934 (2011).","journal-title":"Annals of the rheumatic diseases"},{"key":"60314_CR2","first-page":"S154","volume":"21","author":"M Quinn","year":"2003","unstructured":"Quinn, M. & Emery, P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clinical and experimental rheumatology 21, S154\u2013S157 (2003).","journal-title":"Clinical and experimental rheumatology"},{"key":"60314_CR3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","volume":"43","author":"V Nell","year":"2004","unstructured":"Nell, V. et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43, 906\u2013914 (2004).","journal-title":"Rheumatology"},{"key":"60314_CR4","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1002\/art.27692","volume":"62","author":"MP van der Linden","year":"2010","unstructured":"van der Linden, M. P. et al. Long\u2010term impact of delay in assessment of patients with early arthritis. Arthritis & Rheumatology 62, 3537\u20133546 (2010).","journal-title":"Arthritis & Rheumatology"},{"key":"60314_CR5","first-page":"779","volume":"68","author":"K Mankia","year":"2016","unstructured":"Mankia, K. & Emery, P. Review: Preclinical Rheumatoid Arthritis Progress Toward Prevention. Arthritis &. Rheumatology 68, 779\u2013788 (2016).","journal-title":"Rheumatology"},{"key":"60314_CR6","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1136\/annrheumdis-2015-207871%J","volume":"75","author":"JL Nam","year":"2016","unstructured":"Nam, J. L., Hunt, L., Hensor, E. M. A. & Emery, P. Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms \u2013 a cohort study. Annals of the Rheumatic Diseases. 75, 1452\u20131456, https:\/\/doi.org\/10.1136\/annrheumdis-2015-207871%J (2016).","journal-title":"Annals of the Rheumatic Diseases."},{"key":"60314_CR7","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1136\/annrheumdis-2014-205227","volume":"74","author":"C Rakieh","year":"2015","unstructured":"Rakieh, C. et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Annals of the rheumatic diseases 74, 1659\u20131666 (2015).","journal-title":"Annals of the rheumatic diseases"},{"key":"60314_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the rheumatic diseases 75, 3\u201315 (2016).","journal-title":"Annals of the rheumatic diseases"},{"key":"60314_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s11926-012-0275-1","volume":"14","author":"MK Demoruelle","year":"2012","unstructured":"Demoruelle, M. K. & Deane, K. D. Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Current rheumatology reports 14, 472\u2013480 (2012).","journal-title":"Current rheumatology reports"},{"key":"60314_CR10","doi-asserted-by":"crossref","unstructured":"Winchester, R. In Advances in Immunology Vol. 56 Advances in Immunology 389\u2013466 (1994).","DOI":"10.1016\/S0065-2776(08)60456-3"},{"key":"60314_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/art.1780301102","volume":"30","author":"PK Gregersen","year":"1987","unstructured":"Gregersen, P. K., Silver, J. & Winchester, R. J. The Shared Epitope Hypothesis - an Approach to Understanding the Molecular-Genetics of Susceptibility to Rheumatoid- Arthritis. Arthritis Rheum. 30, 1205\u20131213 (1987).","journal-title":"Arthritis Rheum."},{"key":"60314_CR12","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/art.37964","volume":"65","author":"R Strollo","year":"2013","unstructured":"Strollo, R. et al. Auto\u2010antibodies to post translationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Arthritis & Rheumatism 65, 1702\u20131712 (2013).","journal-title":"Arthritis & Rheumatism"},{"key":"60314_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldmann","year":"1996","unstructured":"Feldmann, M., Brennan, F. M. & Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397\u2013440 (1996).","journal-title":"Annu. Rev. Immunol."},{"key":"60314_CR14","first-page":"429","volume":"30","author":"V Go\u00ebb","year":"2012","unstructured":"Go\u00ebb, V., Walsh, C., Reece, R., Emery, P. & Ponchel, F. Potential role of arthroscopy in the management of inflammatory arthritis. Clinical and Experimental Rheumatology 30, 429\u2013435 (2012).","journal-title":"Clinical and Experimental Rheumatology"},{"key":"60314_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780350702","volume":"35","author":"GS Panayi","year":"1992","unstructured":"Panayi, G. S., Lanchbury, J. S. & Kingsley, G. H. The Importance of the T-Cell in Initiating and Maintaining the Chronic Synovitis of Rheumatoid-Arthritis. Arthritis Rheum. 35, 729\u2013735 (1992).","journal-title":"Arthritis Rheum."},{"key":"60314_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/oxfordjournals.bmb.a072964","volume":"51","author":"M Salmon","year":"1995","unstructured":"Salmon, M. & Gaston, J. The role of lymphocytes in rheumatoid arthritis. Br Med. Bull. 51, 332\u2013345 (1995).","journal-title":"Br Med. Bull."},{"key":"60314_CR17","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/0952-7915(93)90106-3","volume":"5","author":"JS Lanchbury","year":"1993","unstructured":"Lanchbury, J. S. & Pitzalis, C. Cellular Immune-Mechanisms in Rheumatoid-Arthritis and Other Inflammatory Arthritides. Curr. Opin. Immunol. 5, 918\u2013924 (1993).","journal-title":"Curr. Opin. Immunol."},{"key":"60314_CR18","first-page":"37","volume":"7","author":"F Ponchel","year":"2012","unstructured":"Ponchel, F., Vital, E., Kingsbury, S. R. & El-Sherbiny, Y. M. CD4+ T-cell subsets in rheumatoid arthritis. International Journal 7, 37\u201353 (2012).","journal-title":"International Journal"},{"key":"60314_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11926-005-0029-4","volume":"7","author":"SL Mackie","year":"2005","unstructured":"Mackie, S. L., Vital, E. M., Ponchel, F. & Emery, P. Co-stimulatory blockade as therapy for rheumatoid arthritis. Current rheumatology reports 7, 400\u2013406 (2005).","journal-title":"Current rheumatology reports"},{"key":"60314_CR20","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1182\/blood-2002-03-0671","volume":"100","author":"F Ponchel","year":"2002","unstructured":"Ponchel, F. et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 100, 4550\u20134556 (2002).","journal-title":"Blood"},{"key":"60314_CR21","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/rheumatology\/kel089","volume":"45","author":"CA Lawson","year":"2006","unstructured":"Lawson, C. A. et al. Early rheumatoid arthritis is associated with a deficit in the CD4(+)CD25(high) regulatory T cell population in peripheral blood. Rheumatology 45, 1210\u20131217 (2006).","journal-title":"Rheumatology"},{"key":"60314_CR22","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1136\/annrheumdis-2013-203566","volume":"73","author":"F Ponchel","year":"2014","unstructured":"Ponchel, F. et al. An immunological biomarker to predict MTX response in early RA. Annals of the rheumatic diseases 73, 2047\u20132053 (2014).","journal-title":"Annals of the rheumatic diseases"},{"key":"60314_CR23","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1136\/annrheumdis-2015-207991","volume":"75","author":"L Hunt","year":"2016","unstructured":"Hunt, L. et al. T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals. Annals of the Rheumatic Diseases 75, 1884\u20131889 (2016).","journal-title":"Annals of the Rheumatic Diseases"},{"key":"60314_CR24","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.joca.2015.06.018","volume":"23","author":"F Ponchel","year":"2015","unstructured":"Ponchel, F. et al. Changes in peripheral blood immune cell composition in osteoarthritis. Osteoarthritis and cartilage 23, 1870\u20131878 (2015).","journal-title":"Osteoarthritis and cartilage"},{"key":"60314_CR25","doi-asserted-by":"publisher","unstructured":"Gul, H. et al. Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes. Rheumatology, https:\/\/doi.org\/10.1093\/rheumatology\/kez330 (2019).","DOI":"10.1093\/rheumatology\/kez330"},{"key":"60314_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the rheumatic diseases 69, 631\u2013637 (2010).","journal-title":"Annals of the rheumatic diseases"},{"key":"60314_CR27","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. J. Annals of the Rheumatic Diseases. 69, 964\u2013975, https:\/\/doi.org\/10.1136\/ard.2009.126532 (2010).","journal-title":"J. Annals of the Rheumatic Diseases."},{"key":"60314_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/ar1452","volume":"7","author":"F Ponchel","year":"2005","unstructured":"Ponchel, F. et al. IL-7 deficiency and therapy-induced lymphopenia in Rheumatoid Arthritis. Arthritis Res'. Ther. 7, 80\u201392 (2005).","journal-title":"Arthritis Res'. Ther."},{"key":"60314_CR29","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1084\/jem.180.3.1159","volume":"180","author":"D Unutmaz","year":"1994","unstructured":"Unutmaz, D., Pileri, P. & Abrignani, S. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. Journal of Experimental Medicine 180, 1159\u20131164 (1994).","journal-title":"Journal of Experimental Medicine"},{"key":"60314_CR30","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/ard.2007.073833","volume":"67","author":"CH Burgoyne","year":"2008","unstructured":"Burgoyne, C. H. et al. Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Annals Of The Rheumatic Diseases 67, 750\u2013757 (2008).","journal-title":"Annals Of The Rheumatic Diseases"},{"key":"60314_CR31","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen, H., Goodall, J. C. & Hill Gaston, J. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis & Rheumatism 60, 1647\u20131656 (2009).","journal-title":"Arthritis & Rheumatism"},{"issue":"11","key":"60314_CR32","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/rheumatology\/kez162","volume":"58","author":"Agata N Burska","year":"2019","unstructured":"Burska, A. N. et al. Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis. Rheumatology, https:\/\/doi.org\/10.1093\/rheumatology\/kez162 (2019).","journal-title":"Rheumatology"},{"key":"60314_CR33","doi-asserted-by":"crossref","unstructured":"Weissenbach, M. et al. Interleukin\u20106 is a direct mediator of T cell migration. 34, 2895\u20132906 (2004).","DOI":"10.1002\/eji.200425237"},{"key":"60314_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/84701","volume":"7","author":"SC De Rosa","year":"2001","unstructured":"De Rosa, S. C., Herzenberg, L. A., Herzenberg, L. A. & Roederer, M. 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nat. Med. 7, 245\u2013248, https:\/\/doi.org\/10.1038\/84701 (2001).","journal-title":"Nat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60314-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60314-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60314-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:28:26Z","timestamp":1670311706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60314-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60314"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60314-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]},"assertion":[{"value":"26 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3669"}}